Ribociclib Approved in England for Early-Stage Breast Cancer Treatment
Ribociclib is approved for early-stage breast cancer in England, reducing the risk of recurrence by 29%.
Ribociclib is approved for early-stage breast cancer in England, reducing the risk of recurrence by 29%.